Kennebec Savings Bank Purchases 84 Shares of Becton, Dickinson and Company $BDX

Kennebec Savings Bank grew its position in Becton, Dickinson and Company (NYSE:BDX) by 31.2% in the second quarter, HoldingsChannel.com reports. The fund owned 353 shares of the medical instruments supplier’s stock after buying an additional 84 shares during the period. Kennebec Savings Bank’s holdings in Becton, Dickinson and Company were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Becton, Dickinson and Company by 27.4% during the 1st quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier’s stock worth $61,000 after buying an additional 57 shares during the last quarter. NBC Securities Inc. acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $102,000. Merit Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 54.3% during the 1st quarter. Merit Financial Group LLC now owns 5,846 shares of the medical instruments supplier’s stock worth $1,339,000 after buying an additional 2,058 shares during the last quarter. Finally, Whipplewood Advisors LLC lifted its stake in shares of Becton, Dickinson and Company by 67.9% during the 1st quarter. Whipplewood Advisors LLC now owns 880 shares of the medical instruments supplier’s stock worth $202,000 after buying an additional 356 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $190.90 on Thursday. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $188.71 and a two-hundred day simple moving average of $188.20. The stock has a market capitalization of $54.72 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the previous year, the company earned $3.50 EPS. The business’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,023 shares of company stock worth $562,036. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Piper Sandler restated a “neutral” rating and set a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.